CanFite Biopharma Q4 2023 Earnings Significant EPS Surprise as Biotech Focuses on Clinical Pipeline GROW Q1 2026 Earnings Profitability Surprises with EPS of 023 Despite No Revenue Disclosure FUBO Q1 2026 Earnings Narrower Loss Drives Significant EPS Beat GRMN Q1 2026 Earnings EPS Surges Past Estimates Yet Stock Edges Lower TNGX Q1 2026 Earnings ClinicalStage Biotech Reports Slight EPS Miss Stock Slips on No Revenue AGRO Q1 2026 Earnings Deep EPS Miss Sends Shares Lower